Mitf as a marker for predisposition to cancer
AssigneesInstitut Gustave Roussy, Universite Sophia Nice Antipolis, Inserm (Institut National De La Sante Et De La Recherche Medicale)
InventorsRobert Ballotti, Corine Bertolotto, Brigitte Bressac De Paillerets, Mahaut De Lichy, Fabienne Lesueur
Life of this patent
Estimating the term…
Abstract
The present invention relates to a mutant of MITF which is useful as a marker for predisposition to the development of cancer and to uses thereof in diagnosis and preventive treatments, sumoylation being reduced or absent in this mutant.
Claims18
1-13. (canceled)
A method for determining whether a subject has a predisposition or a susceptibility to develop a cancer selected from the group consisting of a cutaneous malignant melanoma, a neuroendocrine cancer, a sarcoma, a neuroblastoma, a nervous system tumor (NST), a lymphoma, a lung cancer, a renal cancer, a breast cancer, a pancreatic cancer, a pediatric tumor, a hematopoietic malignancy, a gastrointestinal cancer, a polycythemia, and combinations thereof, comprising determining in a biological sample from the subject the presence of a mutation in microphthalmia-associated transcription factor (MITF), said mutation reducing or abolishing the sumoylation of MITF and the presence of said mutation indicating that the subject has a predisposition or a susceptibility to develop such cancer.
A method for delaying cancer in a subject carrying a mutation that reduces or abolishes the sumoylation of MITF, comprising administering an effective therapeutic dose of polyphenolic compounds to a subject having reduced or abolished sumoylation of MITF, said effective therapeutic dose delaying the development of a cancer.
Dependencies are inferred from the claim text.